Arcutis Biotherapeutics, Inc. ARQT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $35.07M-18.8% | $43.22M-8.9% | $47.43M-35.1% | $73.05M+36.0% | $53.72M-25.3% | ||
| $189.24M+6.3% | $178.08M+23.7% | $143.95M+21.9% | $118.08M-18.6% | $144.98M-7.4% | ||
| $512.41M+13.0% | $453.45M+19.2% | $380.29M+16.9% | $325.29M+24.2% | $262.01M+22.6% | ||
| $98.77M+26.6% | $77.99M+11.6% | $69.88M+13.7% | $61.48M+4.1% | $59.04M+6.0% | ||
| $438.06M+6.5% | $411.23M+17.8% | $349.22M+4.9% | $332.78M+2.8% | $323.67M-3.6% | ||
| $1.04M-0.3% | $1.04M-14.2% | $1.22M-12.8% | $1.39M-6.8% | $1.5M+43.7% | ||
| $14.25M-3.8% | $14.81M-3.7% | $15.38M-3.5% | $15.94M-3.4% | $16.5M+74.1% | ||
| $460M+6.2% | $432.97M+16.7% | $370.98M+5.3% | $352.43M+2.4% | $344.11M-1.4% | ||
| $51.7M-10.8% | $57.93M-2.8% | $59.63M-18.5% | $73.16M+10.8% | $66.02M+21.2% | ||
| $7.95M— | —— | —— | —— | —— | ||
| $163.2M+25.7% | $129.84M+30.1% | $99.77M-4.0% | $103.94M+14.1% | $91.13M+12.5% | ||
| $101.47M-6.0% | $107.96M+0.4% | $107.5M+0.4% | $107.05M-0.5% | $107.62M+0.4% | ||
| $270.36M+11.0% | $243.49M+14.4% | $212.9M-0.3% | $213.46M+6.0% | $201.45M+5.3% | ||
| 300M0.0% | 300M0.0% | 300M0.0% | 300M0.0% | 300M+2,499,900% | ||
| -$1.15B-1.0% | -$1.14B+1.5% | -$1.16B+0.6% | -$1.16B-1.4% | -$1.15B-2.2% | ||
| $189.65M+0.1% | $189.48M+19.9% | $158.07M+13.7% | $138.97M-2.6% | $142.66M-9.4% | ||
| $460M+6.2% | $432.97M+16.7% | $370.98M+5.3% | $352.43M+2.4% | $344.11M-1.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Arcutis Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 2.68 — current assets exceed current liabilities.
- Where does Arcutis Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.